NCPC(SH:600812) Xin Lang Cai Jing·2025-10-09 09:24Core Viewpoint - The company announced that its wholly-owned subsidiary, Hebei Huamin Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the marketing application of Cefprozil, a second-generation cephalosporin antibiotic [1] Group 1: Product Approval - The approval includes a notification for the marketing of Cefprozil, which is recognized for its strong antibacterial properties and effectiveness in clinical treatments [1] - Cefprozil is indicated for the treatment of bronchitis and other bacterial infections, highlighting its clinical utility [1] Group 2: Product Characteristics - Cefprozil is noted for its resistance to penicillinase, which enhances its effectiveness against certain bacterial strains [1] - The drug is classified as a second-generation cephalosporin, indicating its advanced formulation compared to first-generation antibiotics [1]